Skip to main content
Clinical Trials/CTRI/2018/04/013249
CTRI/2018/04/013249
Completed
Phase 2

A Clinical study to evaluate the safety and efficacy of GastriCare in individuals with Functional Dyspepsia

The Himalaya Drug Company0 sites60 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: null- Subjects who have clinical symptoms of dyspepsia, upper abdominal pain, heart burn, bloating, indigestion, flatulence, abdominal distension, belching and fullness after meal
Sponsor
The Himalaya Drug Company
Enrollment
60
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
November 9, 2016
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1 Subjects of both sexes in the age group of 18 \- 60 years, with gastric problems.
  • 2 Subjects who have clinical symptoms of dyspepsia, upper abdominal pain, heart burn, bloating, indigestion, flatulence, abdominal distension, belching and fullness after meal.
  • 3 Subjects willing to give written informed consent.
  • 4 Subjects who have not participated in similar kind of study in last 4 weeks.

Exclusion Criteria

  • 1 Subjects with established hypertension, renal, hepatic or cardiac failure
  • 2 Endocrine disorders
  • 3 Use of prescription medication to treat gastric problems
  • 4 Pregnant \& lactating women.
  • 5 Not willing to sign informed consent form.

Outcomes

Primary Outcomes

Not specified

Similar Trials